Should I buy Stryker Corporation (SYK) stock or is it too late?
⭐ The most reliable of them, either direction: JP Morgan — 68% of its targets hit on this sector (364 calls tested). It aims for $350 (+24 %), call made on August 1, 2026, maturing on August 1, 2027 (74 d ago).
Firm-by-firm track record on Stryker Corporation
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Stifel | 87 % | +18.7 % | 15 | $330 +17% |
| Wells Fargo | 69 % | +16.9 % | 16 | $348 +23% |
| Citigroup | 67 % | +16.7 % | 15 | $360 +27% |
| Roth MKM | 80 % | +16.7 % | 5 | $456 +61% |
| BTIG | 88 % | +15.3 % | 16 | $316 +12% |
| Piper Sandler | 73 % | +12.8 % | 11 | $390 +38% |
| JP Morgan | 62 % | +12.5 % | 8 | $350 +24% |
| RBC Capital | 75 % | +9.3 % | 16 | $420 +49% |
✅ Reasons to believe
- 82% of analysts rate it a buy (Buy consensus, 17 ratings) — a sign of market conviction.
- Median price target $365, i.e. +29% from the current price ($283).
- The most reliable firm on SYK, UBS (100% hit rate, 2 scored calls), targets $380 (call made on March 17, 2026, maturing on March 17, 2027) (+34%) in its most recent call, and $400 (call made on February 24, 2026, maturing on February 24, 2027) (+42%) in the one coming due soonest.
- 8 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 17 ratings, 3 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
The analyst consensus on SYK
Median target $365 (+29%) · 17 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Stryker Corporation now?
We won't decide for you. The facts: 82% of analysts rate it a buy, median target $365 (+29%), and UBS (most reliable on SYK, 100%) targets $380. Weigh that against valuation (P/E ~29). This is not personalized advice.
Is it too late to invest in Stryker Corporation?
Not according to analysts: the median target ($365) is still +29% above the current price ($283) (most reliable on SYK: UBS, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Stryker Corporation still worth investing in?
It depends on the gap between the price ($283) and its estimated value: analysts target $365 on median (+29%), with 82% buys (most reliable on SYK: UBS, 100%). Cross-check with their real reliability on SYK and the cautions above. Information, not advice.
What's the main risk in buying SYK?
The consensus is not unanimous: of 17 ratings, 3 are neutral.
→ Go deeper: the full Stryker Corporation profile (consensus, analyst reliability, price target, performance).